FAQ on Nutriband Inc. CEO's Recognition as EY Entrepreneur of the Year 2025 Finalist

What is the significance of Gareth Sheridan being named a finalist for the EY Entrepreneur of the Year 2025?

Gareth Sheridan’s recognition highlights his leadership in transforming Nutriband from an early-stage startup into a U.S.-listed life sciences company, focusing on innovative transdermal drug delivery and abuse-deterrent technologies.

What is Nutriband Inc.’s lead product and its purpose?

Nutriband’s lead product is AVERSA, an abuse-deterrent fentanyl patch designed to prevent misuse, abuse, diversion, and accidental exposure of drugs with abuse potential, addressing a critical gap in pain management.

How many entrepreneurs were recognized in the EY Entrepreneur of the Year 2025 awards?

27 Irish entrepreneurs were recognized as finalists in the EY Entrepreneur of the Year 2025 awards, selected from across 24 companies generating more than €1 billion in annual revenue.

What will the finalists of the EY Entrepreneur of the Year 2025 participate in?

Finalists will participate in a CEO retreat in Japan and compete for the overall Entrepreneur of the Year title, to be awarded at a gala event in November.

Where can I find more information about Nutriband Inc.?

More information about Nutriband Inc. can be found on their website at www.Nutriband.com.

Where can investors find the latest news and updates about Nutriband Inc.?

Investors can find the latest news and updates relating to Nutriband Inc. (NASDAQ: NTRB) in the company’s newsroom at https://ibn.fm/NTRB.

What is the focus of Nutriband Inc.’s business?

Nutriband Inc. is primarily engaged in the development of a portfolio of transdermal pharmaceutical products, with a focus on abuse-deterrent technologies.

What is the AVERSA technology?

AVERSA technology is an abuse-deterrent technology developed by Nutriband that can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.